ArticleJournal of hematology & oncology2020

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.

Xinhua Xiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.